GlassScriptPhysician profile
Jennifer Davis Edwards
NPI 1972763886
$1,499.96
in general payments reported to CMS, 2019-2025
26 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $177 · 2023: $350 · 2024: $398 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $216.36 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $189.73 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $188.63 | 2021-2025 | |
| Boston Scientific Corporation | $118.00 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $89.12 | 2022-2025 | |
| Glaxosmithkline, LLC. | $87.80 | 2021-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $84.66 | 2023-2025 | Freestyle Libre 3, Octrode |
| Amgen INC. | $68.35 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Currax Pharmaceuticals LLC | $43.79 | 2024-2025 | Contrave |
| Inari Medical, INC. | $41.32 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Esperion Therapeutics, INC. | $39.47 | 2021-2024 | Nexletol |
| Baxter Healthcare | $37.32 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Ani Pharmaceuticals, INC. | $34.74 | 2024 | Purified Cortrophin Gel |
| Stryker Corporation | $29.77 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $29.67 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $28.32 | 2023-2024 | Quviviq |
| Horizon Therapeutics Plc | $26.24 | 2023 | Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $19.85 | 2022 | |
| Cranial Technologies, INC | $19.03 | 2025 | Doc Band |
| Amarin Pharma, INC. | $18.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.93 | 2021 | |
| Shield Therapeutics INC | $17.70 | 2024 | |
| Paratek Pharmaceuticals, INC. | $14.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.12 | 2023 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $12.61 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.